MARKET

MCRB

MCRB

Seres Therapeutics Inc
NASDAQ
13.96
+0.56
+4.18%
After Hours: 14.23 +0.27 +1.93% 17:46 02/06 EST
OPEN
13.50
PREV CLOSE
13.40
HIGH
14.32
LOW
13.50
VOLUME
63.89K
TURNOVER
--
52 WEEK HIGH
29.98
52 WEEK LOW
6.53
MARKET CAP
126.29M
P/E (TTM)
23.70
1D
5D
1M
3M
1Y
5Y
1D
Seres Therapeutics: Strong SER-155 Data, But Dilution Risk Now Warrants A 'Hold'
Seeking Alpha · 19h ago
UPDATE 1-Huawei-backed Aito teams up with UAE dealer to kick off exports
Reuters · 1d ago
Weekly Report: what happened at MCRB last week (0126-0130)?
Weekly Report · 5d ago
Weekly Report: what happened at MCRB last week (0119-0123)?
Weekly Report · 01/26 10:14
Weekly Report: what happened at MCRB last week (0112-0116)?
Weekly Report · 01/19 10:20
Weekly Report: what happened at MCRB last week (0105-0109)?
Weekly Report · 01/12 10:19
Seres announces publications in Nature Medicine, Journal of Infectious Diseases
TipRanks · 01/06 12:22
Seres Therapeutics Publishes New Data In Nature Medicine And Journal Of Infectious Diseases Supporting VOWST Mechanism And Broader Live Biotherapeutics Platform
Benzinga · 01/06 12:09
More
About MCRB
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.

Webull offers Seres Therapeutics Inc stock information, including NASDAQ: MCRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MCRB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MCRB stock methods without spending real money on the virtual paper trading platform.